Related Experiment Video

Updated: Aug 8, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Targeting epidermal growth factor receptor signaling: early results and future trends in oncology

Agustín Lage1, Tania Crombet, Gisela González

  • 1Center of Molecular Immunology, 216 St & 15th Ave, Playa, P.O. Box 16040, Havana City 11600, Cuba. lage@ict.cim.sld.cu

Annals of Medicine
|September 4, 2003
PubMed

Insights

Epidermal growth factor receptor (EGFR) is a promising anti-cancer target, especially for resistant tumors. New therapies like tyrosine kinase inhibitors and antibodies show early promise but require further study and combination strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Epidermal growth factor receptor (EGFR) is overexpressed in many carcinomas.
  • EGFR overexpression correlates with malignant behaviors like proliferation, apoptosis evasion, migration, and angiogenesis.
  • EGFR is a key target for novel anti-cancer therapies, particularly in chemotherapy-resistant cancers.

Purpose of the Study:

  • To review the role of EGFR as a therapeutic target in cancer.
  • To discuss current and emerging anti-EGFR agents in clinical trials.
  • To explore future directions for combination therapies targeting the EGFR pathway.

Main Methods:

  • Review of current literature on EGFR in cancer therapy.
  • Analysis of clinical trial data for anti-EGFR agents.
  • Discussion of potential combination strategies for enhanced efficacy.

Main Results:

  • Several anti-EGFR agents, including small molecule inhibitors, monoclonal antibodies, and cancer vaccines, are in clinical trials.
  • Early clinical results indicate antitumor activity, though larger trials are needed for confirmation.
  • Adverse effects like skin rash and diarrhea are noted, with toxicity profiles distinct from chemotherapy and radiotherapy.

Conclusions:

  • EGFR represents a significant therapeutic target for various carcinomas, especially those resistant to conventional treatments.
  • Combination therapies involving anti-EGFR agents with other treatments, including vaccines and inhibitors of related pathways, are crucial for overcoming treatment resistance.
  • Future research should focus on optimizing treatment schedules and exploring synergistic combinations to effectively manage complex, robust EGFR signaling in cancer.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: